JP Morgan Call 1000 REGN 15.11.20.../ DE000JK41ZA6 /
| 2024-06-11 8:44:54 AM | Chg.0.000 | Bid1:51:14 PM | Ask1:51:14 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.690EUR | 0.00% | 0.670 Bid Size: 5,000 |
0.700 Ask Size: 5,000 |
Regeneron Pharmaceut... | 1,000.00 USD | 2024-11-15 | Call |
GlobeNewswire
1:00 PM
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire
06-05
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
06-04
Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire
06-03
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroG...
GlobeNewswire
05-31
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire
05-31
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire
05-31
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire
05-31
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire
05-28
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
05-23
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...
GlobeNewswire
05-21
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswire
05-20
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
05-20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
05-20
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
05-20
Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encou...
GlobeNewswire
05-17
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...
GlobeNewswire
05-14
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...
GlobeNewswire
05-13
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
05-10
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
05-09
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company P...
